Circulating tumour cell-derived xenograft as a preclinical platform for metastatic breast cancer
A patient's circulating tumor cells successfully grew into tumors in mice and responded to specific drugs, demonstrating a potential personalized drug-testing platform.
A CTC-derived xenograft from a single metastatic breast cancer patient was successfully established, enriched in breast cancer stem cells, and showed sensitivity to carboplatin and vandetanib in vitro and in vivo. While a promising preclinical platform concept, this is a single patient derivation with no clinical outcomes data.
What the study was
- Study design
- Preclinical model development (in vivo/in vitro CTC-derived xenograft)
- Population
- CTCs from single metastatic breast cancer patient
- Sample size
- 1
- Category
- Drug Development
- Maturity
- Exploratory
- Journal
- British Journal of Cancer
Why it surfaced
Preclinical model development from single patient. British Journal of Cancer. Too preliminary for pipeline-ready insights. Score capped at 5 for non-human study (xenograft in mice); further reduced to 4 given single-patient source.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.